Could PD-L1 positivity be associated with venous thrombosis in patients with non-small cell lung cancer?

The risk of venous thromboembolism (VTE) is increased in non-small cell lung cancer (NSCLC), and defining at-risk patients is important. Thus, we aimed to assess the association between programmed cell death ligand 1 (PD-L1) expression and VTE [pulmonary embolism (PE), deep venous thrombosis (DVT)]...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and thrombolysis 2023-02, Vol.55 (2), p.382-391
Hauptverfasser:	Söyler, Yasemin, Akın Kabalak, Pınar, Kavurgacı, Suna, Akyürek, Nalan, Demirağ, Funda, Yılmaz, Ülkü
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticoagulants - therapeutic use Apoptosis B7-H1 Antigen - therapeutic use Biopsy Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - drug therapy Cardiology Cell death Embolism Hematology Humans Immunohistochemistry Lung cancer Lung Neoplasms - complications Medicine Medicine & Public Health Metastases Multivariate analysis Non-small cell lung carcinoma PD-L1 protein Pulmonary Embolism - drug therapy Pulmonary embolisms Retrospective Studies Risk Factors Small cell lung carcinoma Thromboembolism Thrombosis Venous Thromboembolism - drug therapy Venous Thrombosis - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!